Noah Rosenberg takes chief medical officer role at Esperion

Will develop and manage the firm’s clinical programmes

Noah Rosenberg has taken over as chief medical officer (CMO) at Esperion Therapeutics and will lead the Esperion clinical advisory board and develop and manage the company's clinical programmes. He will also manage the regulatory review process for the company's investigational therapies to treat cardiovascular and metabolic diseases.

Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.

‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.

You may also like

Research & Development
UNC Charlotte and BioCytics target cancer ‘dark genome’ with multi-omics platform

UNC Charlotte and BioCytics target cancer ‘dark genome’ with multi-omics platform

Two-year research collaboration will combine long-read sequencing, immune profiling and computational analysis to identify viral and genomic drivers of cancer and support personalised treatment decisions
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Manufacturing
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Brings decentralised, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
Manufacturing
ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products
Design & Build
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours
Subscribe now